Related Experiment Video
Updated: Jul 1, 2026
05:51
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
25.8K
Novel Approaches to Studying SLC13A5 Disease
1Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA.
Metabolites
|February 23, 2024
Summary
The sodium citrate transporter (NaCT) SLC13A5 is crucial for health, causing epilepsy when faulty and offering metabolic disease protection when inhibited. New stem cell technologies help study its complex human roles.
Area of Science:
- Biochemistry
- Genetics
- Cell Biology
Background:
- The sodium citrate transporter (NaCT) SLC13A5 has diverse roles, linked to neonatal epilepsy and metabolic disease.
- Understanding SLC13A5 mechanisms is challenging due to limitations in current animal models of human physiology.
Purpose of the Study:
- This review explores innovative technologies to study SLC13A5.
- It aims to bridge knowledge gaps regarding the transporter's cellular and molecular functions in human disease.
Main Methods:
- Overview of SLC13A5 variants and expression in human disease.
- Discussion of patient-specific induced pluripotent stem cell (iPSC) generation.
- Summary of iPSC differentiation into neurons, hepatocytes, and organoids.
Main Results:
- Patient-specific iPSCs offer a powerful platform for studying SLC13A5.
- Differentiated cells and organoids model human physiology for mechanistic studies.
- These models facilitate investigation into SLC13A5-related disorders.
Conclusions:
- Innovative stem cell technologies are essential for understanding SLC13A5.
- Patient-derived iPSC models provide unprecedented insights into human transporter function.
- These platforms are key to elucidating SLC13A5's role in disease and potential therapeutics.
